[go: up one dir, main page]

EA200200975A1 - Гидрохлорид 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси] бензил]тиазолидин-2,4-диона - Google Patents

Гидрохлорид 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси] бензил]тиазолидин-2,4-диона

Info

Publication number
EA200200975A1
EA200200975A1 EA200200975A EA200200975A EA200200975A1 EA 200200975 A1 EA200200975 A1 EA 200200975A1 EA 200200975 A EA200200975 A EA 200200975A EA 200200975 A EA200200975 A EA 200200975A EA 200200975 A1 EA200200975 A1 EA 200200975A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyridyl
benzyl
amino
methyl
hydrochloride
Prior art date
Application number
EA200200975A
Other languages
English (en)
Other versions
EA005115B1 (ru
Inventor
Эндрю Симон Крейг
Original Assignee
Смитклайн Бичам Плс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Смитклайн Бичам Плс filed Critical Смитклайн Бичам Плс
Publication of EA200200975A1 publication Critical patent/EA200200975A1/ru
Publication of EA005115B1 publication Critical patent/EA005115B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение раскрывает, по существу, не гидратированный и не гигроскопичный или слегка гигроскопичный гидрохлорид 5-[4-[2-(N-метил-N-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона; фармацевтическую композицию, содержащую такое соединение, способ получения такого соединения и применение такого соединения в медицине.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200975A 2000-03-14 2001-03-14 Гидрохлорид 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона EA005115B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0006133.3A GB0006133D0 (en) 2000-03-14 2000-03-14 Novel pharmaceutical
PCT/GB2001/001131 WO2001068646A1 (en) 2000-03-14 2001-03-14 Hydrochloride salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

Publications (2)

Publication Number Publication Date
EA200200975A1 true EA200200975A1 (ru) 2003-02-27
EA005115B1 EA005115B1 (ru) 2004-10-28

Family

ID=9887600

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200975A EA005115B1 (ru) 2000-03-14 2001-03-14 Гидрохлорид 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона

Country Status (30)

Country Link
US (2) US7074811B2 (ru)
EP (1) EP1265893B1 (ru)
JP (1) JP2003527393A (ru)
KR (1) KR100746813B1 (ru)
CN (1) CN100516062C (ru)
AP (1) AP1545A (ru)
AT (1) ATE302202T1 (ru)
AU (1) AU777987B2 (ru)
BG (1) BG65924B1 (ru)
BR (1) BR0108870A (ru)
CA (1) CA2403109A1 (ru)
CZ (1) CZ20023074A3 (ru)
DE (1) DE60112729T2 (ru)
DK (1) DK1265893T3 (ru)
DZ (1) DZ3316A1 (ru)
EA (1) EA005115B1 (ru)
ES (1) ES2243458T3 (ru)
GB (1) GB0006133D0 (ru)
HU (1) HUP0300158A3 (ru)
IL (2) IL151425A0 (ru)
MA (1) MA25658A1 (ru)
MX (1) MXPA02008972A (ru)
NO (1) NO323448B1 (ru)
NZ (1) NZ520910A (ru)
OA (1) OA12229A (ru)
PL (1) PL357283A1 (ru)
SK (1) SK286399B6 (ru)
UA (1) UA73974C2 (ru)
WO (1) WO2001068646A1 (ru)
ZA (1) ZA200207292B (ru)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021865D0 (en) * 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0023971D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
EP1448559B1 (en) * 2001-11-21 2006-12-27 Smithkline Beecham Plc 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thereof; and its use as pharmaceutical active ingredient
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
WO2006018853A2 (en) 2004-08-19 2006-02-23 Hetero Drugs Limited Novel polymorphs of efavirenz
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
NZ573360A (en) 2006-05-04 2012-08-31 Boehringer Ingelheim Int Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
US20090076093A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched rosiglitazone
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
MX2011006713A (es) 2008-12-23 2011-07-13 Boehringer Ingelheim Int Formas salinas de compuesto organico.
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
US8106111B2 (en) * 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2013010964A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849754B1 (en) 2012-05-14 2022-09-14 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US120078A (en) * 1871-10-17 Improvement in revolving flower-stands
US137940A (en) * 1873-04-15 Improvement in elevators
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group P.L.C., Brentford Substituierte Thiazolidindionderivate
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
GB9413975D0 (en) * 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
GB9124513D0 (en) * 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5741803A (en) * 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
NZ501260A (en) 1997-06-18 2002-09-27 Smithkline Beecham P Treatment of diabetes with thiazolidinedione and metformin
US20020137940A1 (en) * 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
US6664278B2 (en) * 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9909075D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
GB9909041D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
TR200103061T2 (tr) 1999-04-23 2002-05-21 Smithkline Beecham P.L.C. Yeni farmasötik madde.
MXPA01010821A (es) 1999-04-23 2003-09-04 Smithkline Beecham Plc Forma poliformica de sal de acido maleico de 5-[4-[2 -(n-metil -n-(2- piridil) amino ) etoxi] bencil ] tiazolidin-2, 4-diona.
AU4307200A (en) 1999-04-23 2000-11-10 Smithkline Beecham Plc Novel pharmaceutical
HU225919B1 (en) 1999-12-18 2007-12-28 Richter Gedeon Nyrt Thiazolidine-derivatives, process for their preparation pharmaceutical and intermediates
CN1277965A (zh) 2000-06-14 2000-12-27 中国医药研究开发中心 盐酸罗格列酮及其应用
GB0021865D0 (en) 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical

Also Published As

Publication number Publication date
IL151425A0 (en) 2003-04-10
BG107012A (bg) 2003-04-30
KR100746813B1 (ko) 2007-08-06
PL357283A1 (en) 2004-07-26
EA005115B1 (ru) 2004-10-28
UA73974C2 (en) 2005-10-17
OA12229A (en) 2003-11-07
EP1265893B1 (en) 2005-08-17
HK1052502A1 (en) 2003-09-19
ES2243458T3 (es) 2005-12-01
AP1545A (en) 2006-01-12
CA2403109A1 (en) 2001-09-20
DE60112729T2 (de) 2006-06-08
HUP0300158A3 (en) 2005-04-28
AU777987B2 (en) 2004-11-11
US7074811B2 (en) 2006-07-11
CN100516062C (zh) 2009-07-22
US20040152901A1 (en) 2004-08-05
NO20024307D0 (no) 2002-09-09
BG65924B1 (bg) 2010-05-31
AU4084301A (en) 2001-09-24
DZ3316A1 (fr) 2001-09-20
NO323448B1 (no) 2007-05-07
NZ520910A (en) 2004-06-25
IL151425A (en) 2009-08-03
US20050267162A1 (en) 2005-12-01
WO2001068646A1 (en) 2001-09-20
DK1265893T3 (da) 2005-11-14
MXPA02008972A (es) 2003-02-10
HUP0300158A2 (en) 2003-05-28
BR0108870A (pt) 2002-12-17
EP1265893A1 (en) 2002-12-18
ATE302202T1 (de) 2005-09-15
KR20020079998A (ko) 2002-10-21
CZ20023074A3 (cs) 2003-02-12
MA25658A1 (fr) 2002-12-31
JP2003527393A (ja) 2003-09-16
ZA200207292B (en) 2003-05-06
NO20024307L (no) 2002-09-09
GB0006133D0 (en) 2000-05-03
CN1358184A (zh) 2002-07-10
DE60112729D1 (de) 2005-09-22
AP2002002600A0 (en) 2002-09-30
SK13302002A3 (sk) 2003-02-04
SK286399B6 (sk) 2008-09-05

Similar Documents

Publication Publication Date Title
EA200200975A1 (ru) Гидрохлорид 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси] бензил]тиазолидин-2,4-диона
EA200300345A1 (ru) Гидрохлоридная соль 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона
EA200300234A1 (ru) Тартратные соли производного тиазолидиндиона
CY1106226T1 (el) Μεσυλικο αλας 5-[4-[2-(ν-μεθυλ-ν-(2-πυριδυλ)αμινο)αιθοξυ]βενζυλ]θειαζολιδινο-2,4-διονης
EA200101102A1 (ru) Новый фармацевтический препарат
EA200300005A1 (ru) Соль тиазолидиндиона для лечения сахарного диабета
EA200300231A1 (ru) Тартратные соли производного тиазолидиндиона
DK1446404T3 (da) Rosiglitazonedisylater og deres anvendelse som antidiabetika
EA200300230A1 (ru) Тартратная соль производного тиазолидиндиона
DK1315724T3 (da) Thiazolidindionderivat og dets anvendelse som antidiabetikum
EA200300422A1 (ru) Натриевые соли 5-[4-[2-( n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона
EA200300004A1 (ru) Гидроиодид 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона в качестве фармацевтического препарата
EA200300232A1 (ru) Тартратные соли производного тиазолидиндиона
EA200300423A1 (ru) Производное тиазолидиндиона и его применение в качестве противодиабетического лекарственного средства
SI1448559T1 (sl) 5-(4-(2-(n-metil-n-(2-piridil)amino)etoksi)benzil-tiazolidin-2,4-dion- benzensulfonat; postopek za njegovo pripravo; njegovi polimorfi i, ii, iii; in njegova uporaba kot farmacevtska uäśinkovina
ECSP003435A (es) Nuevos compuestos

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU